Inflammation and its association with glucose disorders and cardiovascular disease

Treatments in Endocrinology

Volumn 2, Issue 2, 2003, Pages 85-94

  Barzilay, Joshua ^a,b,d   Freedland, Eric ^c  

^a Kaiser Permanente of Georgia ^*  (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d KAISER PERMANENTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; ANTIDIABETIC AGENT; ANTIINFLAMMATORY AGENT; ANTIRHEUMATIC AGENT; DOCOSAHEXAENOIC ACID; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FISH OIL; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; INTERLEUKIN 8; OMEGA 3 FATTY ACID; VASCULAR CELL ADHESION MOLECULE 1;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CYTOKINE PRODUCTION; DIABETES MELLITUS; DISEASE ACTIVITY; DISEASE ASSOCIATION; ENDOTHELIUM LESION; GLUCOSE BLOOD LEVEL; HUMAN; INFLAMMATION; INSULIN RESISTANCE; MEDICAL RESEARCH; PATHOPHYSIOLOGY; PREDICTION; PRIORITY JOURNAL; REVIEW;

CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS; ENDOTHELIUM, VASCULAR; HUMANS; INFLAMMATION; INSULIN RESISTANCE; PROSPECTIVE STUDIES;

EID: 0041357080     PISSN: 11756349     EISSN: None     Source Type: Journal    
DOI: 10.2165/00024677-200302020-00002     Document Type: Review

References (115)

1. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340: 448-54
2. Medzhitov R, Janeway C. Innate immunity. N Engl J Med 2000; 343: 338-44
3. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999; 340: 115-26
4. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105: 1135-43
5. Ridker PM, Rifai N, Rose L, et al. Comparison of c-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347: 1557-65
6. Ridker PM. Inflammation, atherosclerosis, and cardiovascular risk: an epidemiologic view. Blood Coagul Fibrinolysis 1999; 10 Suppl. 1: S9-12
7. Visser M, Bouter LM, McQuillan GM, et al. Elevated C-reactive protein levels in overweight and obese adults. JAMA 1999; 282: 2131-5
8. Ford ES. Body mass index, diabetes, and C-reactive protein among US adults. Diabetes Care 1999; 22: 1971-7
9. Das UN. Is obesity an inflammatory condition? Nutrition 2001; 17: 953-66
10. Levi M, Ten Cate H. Disseminated intravascular coagulation. N Engl J Med 1999; 341: 586-92
11. van der Poll T, de Jonge E, Levi M. Regulatory role of cytokines in disseminated intravascular coagulation. Semin Thromb Hemost 2001; 27: 639-51
12. Sakkinen PA, Wahl P, Cushman M, et al. Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome. Am J Epidemiol 2000; 152: 897-907
13. Tracy RP, Bovill EG, Yanez D, et al. Fibrinogen and factor VIII, but not factor VII, are associated with measures of subclinical cardiovascular disease in the elderly: results from the cardiovascular health study. Arterioscler Thromb Vasc Biol 1995; 15: 1269-79
14. Hotamisligil GS, Spiegelman BM. Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes 1994; 43: 1271-8
15. Hotamisligil GS, Peraldi P, Budavari A, et al. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha and obesity induced insulin resistance. Science 1996; 271: 665-8
16. Skolnik EY, Marcusohn J. Inhibition of insulin receptor signaling by TNF: potential role in obesity and non-insulin-dependent diabetes mellitus. Cytokine Growth Factor Rev 1996; 7: 162-73
17. Hotamisligil GS. Mechanisms of TNF-alpha-induced insulin resistance. Exp Clin Endocrinol Diabetes 1999; 107: 119-25
18. Hirosumi J, Tuncman G, Chang L, et al. A central role for JNK in obesity and insulin resistance. Nature 2002; 420: 333-6
19. Crook M, Tutt P, Pickup JC. Elevated serum sialic acid concentration in noninsulin-dependent diabetes and its relationship to blood-pressure and retinopathy. Diabetes Care 1993; 16: 57-60
20. Pickup JC, Mattock MB, Crook MA, et al. Serum sialic acid concentration and coronary heart disease in NIDDM. Diabetes Care 1995; 18: 1100-3
21. Pickup JC, Mattock MB, Chusney GD, et al. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 1997; 40: 1286-92
22. Nilsson J, Jovinge S, Niemann A, et al. Relation between plasma tumor necrosis factor-alpha and insulin sensitivity in elderly men with non-insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol 1998; 18: 1199-202
23. Festa A, D'Agostino R, Howard G, et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000; 102: 42-7
24. Frohlich M, Imhof A, Berg G, et al. Association between C-reactive protein and features of the metabolic syndrome: a population-based study. Diabetes Care 2000; 23: 1835-9
25. Mansfield MW, Heywood DM, Grant PJ. Circulating levels of factor VII, fibrinogen, and von Willebrand factor and features of insulin resistance in first-degree relatives of patients with NIDDM. Circulation 1996; 94: 2171-6
26. Herlihy OM, Barrow BA, Grant PJ, et al. Hyperglycaemic siblings of type II (noninsulin-dependent) diabetic patients have increased PAI-1, central obesity and insulin resistance compared with their paired normoglycaemic siblings. Diabetologia 2002; 45: 635-41
27. Ford ES, Cogswell ME. Diabetes and serum ferritin concentration among US adults. Diabetes Care 1999; 22: 1978-83
28. Wu TJ, Dorn JP, Donahue RP, et al. Associations of serum C-reactive protein with fasting insulin, glucose, and glycosylated hemoglobin: the Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol 2002; 155: 65-71
29. Nakanishi N, Suzuki K, Tatara K. White blood cell count and clustered features of metabolic syndrome in Japanese male office workers. Occup Med (Lond) 2002; 52: 213-8
30. Nakanishi N, Sato M, Shirai K, et al. Associations between white blood cell count and features of the metabolic syndrome in Japanese male office workers. Ind Health 2002; 40: 273-7
31. Gonzalez F, Thusu K, Abdel-Rahman E, et al. Elevated serum levels of tumor necrosis factor alpha in normal-weight women with polycystic ovary syndrome. Metabolism 1999; 48: 437-41
32. Kelly CC, Lyall H, Petrie JR, et al. Low grade inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 2001; 86: 2453-5
33. Srihara M, Reichelt A, Opperman MLR, et al. Total sialic acid and associated elements of the metabolic syndrome in women with and without previous gestational diabetes. Diabetes Care 2002; 25: 1331-5
34. Schmidt MI, Duncan BB, Sharrett AR, et al. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities Study): a cohort study. Lancet 1999; 353: 1649-52
35. Pradhan AD, Manson JE, Rifai N, et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001; 286: 327-34
36. Barzilay JI, Abraham L, Heckbert SR, et al. The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study. Diabetes 2001; 50: 2384-9
37. Vozarova B, Weyer C, Lindsay RS, et al. High white blood cell count is associated with a worsening of insulin sensitivity and predicts the development of type 2 diabetes. Diabetes 2002; 51: 455-61
38. Lindsay RS, Krakoff J, Hanson RL, et al. Gamma globulin levels predict type 2 diabetes in the Pima Indian population. Diabetes 2001; 50: 1598-603
39. Hansson GK, Libby P, Schonbeck U, et al. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res 2002; 91: 281-91
40. Festa A, D'Agostino R, Tracy RP, et al. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 2002; 51: 1131-7
41. Duncan BB, Schmidt MI, Offenbacher S, et al. Factor VIII and other hemostasis variables are related to incident diabetes in adults. The Atherosclerosis Risk in Communities (ARIC) Study. Diabetes Care 1999; 22: 767-72
42. Ford ES. Leukocyte count, erythrocyte sedimentation rate, and diabetes incidence in a national sample of US adults. Am J Epidemiol 2002; 155: 57-64
43. Han TS, Sattar N, Williams K, et al. Prospective study of c-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care 2002; 25: 2016-21
44. Nakanishi N, Yoshida H, Matsuo Y, et al. White blood-cell count and the risk of impaired fasting glucose or type II diabetes in middle-aged Japanese men. Diabetologia 2002; 45: 42-8
45. Freeman DJ, Norrie I, Caslake MJ, et al. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 2002; 51: 1596-600
46. Vozarova B, Weyer C, Hanson K, et al. Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion. Obes Res 2001; 9: 414-7
47. Temelkova-Kurktschiev T, Siegert G, Bergmann S, et al. Subclinical inflammation is strongly related to insulin resistance but not to impaired insulin secretion in a high risk population for diabetes. Metabolism 2002; 51: 743-9
48. Verma S, Anderson T. Fundamentals of endothelial function for the clinical cardiologist. Circulation 2002; 105: 546-9
49. Gray RP, Yudkin JS, Patterson DL. Plasminogen activator inhibitor: a risk factor for myocardial infarction in diabetic patients. Br Heart J 1993; 69: 228-32
50. Nagi DK, Mohamed Ali V, Jain SK, et al. Plasminogen activator inhibitor (PAI-1) activity is elevated in Asian and Caucasian subjects with non-insulin-dependent (type 2) diabetes but not in those with impaired glucose tolerance (IGT) or nondiabetic Asians. Diabet Med 1996; 13: 59-64
51. Yudkin JS, Stehouwer CDA, Emeis JJ, et al. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue. Arterioscler Thromb Vase Biol 1999; 19: 972-8
52. Chen N-G, Holmes M, Reaven GM. Relationship between insulin resistance, soluble adhesion molecules, and mononuclear cell binding in healthy volunteers. J Clin Endocrinol Metab 1999; 84: 3485-9
53. Stuhlinger MC, Abbasi F, Chu JW, et al. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA 2002; 287: 1420-6
54. Boger RH, Bode-Boger SM, Szuba A, et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 1998; 98: 1842-7
55. Hak AE, Pols HA, Stehouwer CD, et al. Markers of inflammation and cellular adhesion molecules in relation to insulin resistance in nondiabetic elderly: the Rotterdam study. J Clin Endocrinol Metab 2001; 86: 4398-405
56. Zwaka TP, Hambach V, Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation 2001; 103: 1194-7
57. Ito A, Tsao PS, Adimoolan S, et al. Novel mechanism for eridothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydolase. Circulation 1999; 99: 3092-5
58. Penn MS, Topol EJ. Tissue factor, the emerging link between inflammation, thrombosis, and vascular remodeling. Circ Res 2001; 89: 1-2
59. Pasceri V, Chang J, Willerson JT, et al. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 2001; 103: 2531-4
60. Aljada A, Ghanim H, Assian E, et al. Tumor necrosis factor-alpha inhibits insulin-induced increase in endothelial nitric oxide synthase and reduces insulin receptor content and phosphorylation in human aortic endothelial cells. Metabolism 2002; 51: 487-91
61. Hennes MM, O'Shaughnessy IM, Kelly TM, et al. Insulin-resistant lipolysis in abdominally obese hypertensive individuals. Hypertension 1996; 28: 120-6
62. Inoguchi T, Li P, Umeda F, et al. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes 2000; 49: 1939-45
63. Facchini FS, Humphreys MH, DoNascimento CA, et al. Relation between insulin resistance and plasma concentrations of lipid hydroperoxides, carotenoids, and tocopherols. Am J Clin Nutr 2000; 72: 776-9
64. Nadler J, Buchanan T, Natarajan R, et al. Magnesium deficiency produces insulin resistance and increased thromboxane synthesis. Hypertension 1993; 21: 1024-9
65. Caballero AE, Arora S, Saouaf R, et al. Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes. Diabetes 1999; 48: 1856-62
66. Weyer C, Yudkin JS, Stehouwer CD, et al. Humoral markers of inflammation and endothelial dysfunction in relation to adiposity and in vivo insulin action in Pima Indians. Atherosclerosis 2002; 161: 233-42
67. Pickup JC, Chusney GD, Thomas SM, et al. Plasma interleukin-6, tumor necrosis factor alpha and blood cytokine production in type 2 diabetes. Life Sci 2000; 67: 291-300
68. Pinkney JH, Stehouwer CD, Coppack SW, et al. Endothelial dysfunction: cause of the insulin resistance syndrome. Diabetes 1997; 46 Suppl. 2: S9-S13
69. Wei M, Schwertner HA, Blair SN. The association between physical activity, physical fitness, and type 2 diabetes mellitus. Compr Ther 2000; 26: 176-82
70. Wei M, Gibbons LW, Kampert JB, et al. Low cardiorespiratory fitness and physical inactivity as predictors of mortality in men with type 2 diabetes. Ann Intern Med 2000; 132: 605-11
71. Wei M, Kampert JB, Barlow CE, et al. Relationship between low cardiorespiratory fitness and mortality in normal-weight, overweight, and obese men. JAMA 1999; 282: 1547-53
72. Maiorana A, O'Driscoll G, Cheetham C, et al. The effect of combined aerobic and resistance exercise training on vascular function in type 2 diabetes. J Am Coll Cardiol 2001; 38: 860-6
73. Ziccardi P, Nappo F, Giugliano G, et al. Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation 2002; 105: 804-9
74. Perscghin G, Price TB, Petersen KF, et al. Increased glucose transport-phosphorylation and muscle glycogen synthesis after exercise training in insulin-resistant subjects. N Engl J Med 1996; 335: 1357-62
75. Buemann B, Tremblay A. Effects of exercise training on abdominal obesity and related metabolic complications. Sports Med 1996; 21: 191-212
76. Adamopoulos S, Parissis J, Karatzas D, et al. Physical training modulates proinflammatory cytokines and the soluble Fas/soluble Fas ligand system in patients with chronic heart failure. J Am Coll Cardiol 2002; 39: 653-63
77. Smith JK, Dykes R, Douglas JE, et al. Long-term exercise and atherogenic activity of blood mononuclear cells in persons at risk of developing ischemic heart disease. JAMA 1999; 281: 1722-7
78. van Dam RM, Rimm EB, Willett WC, et al. Dietary patterns and risk for type 2 diabetes mellitus in US men. Ann Intern Med 2002; 136: 201-9
79. Jarvi A, Karlstrom B, Granfeldt Y, et al. Improved glycemic control and lipid profile and normalized fibrinolytic activity on a low-glycemic index diet in Type 2 diabetic patients. Diabetes Care 1999; 22: 10-8
80. Salmeron JM, Manson JE, Stampfer M, et al. Dietary fiber, glycemic load, and risk of non-insulin-dependent diabetes mellitus in women. JAMA 1997; 277: 472-7
81. Salmeron JA, Ascherio A, Rimm E, et al. Dietary fiber, glycemic load, and risk of NIDDM in men. Diabetes Care 1997; 20: 545-9
82. Liu S, Manson JE, Buring JE, et al. Relation between a diet with a high glycemic load and plasma concentrations of high-sensitivity C-reactive protein in middle-aged women. Am J Clin Nutr 2002; 75: 492-8
83. Ascherio A, Willett W. Health effects of trans fatty acids. Am J Clin Nutr 1997; 66 (4 Suppl.): S1006-10
84. Mensink RP, Katan MB. Effect of dietary trans fatty acids on high-density and low-density lipoprotein cholesterol levels in healthy subjects. N Engl J Med 1990; 323: 439-45
85. Ratnayake W, Chen Z. Trans, n-3, and n-6 fatty acids in Canadian human milk. Lipids 1996; 31 Suppl.: S279-82
86. Li D, Ng A, Mann N, et al. Contribution of meat fat to dietary arachidonic acid. Lipids 1998; 33: 437-40
87. Crawford M. Fatty-acid ratios in free-living and domestic animals: possible implications for atheroma. Lancet 1968; 1: 1329-33
88. Endres S. Messengers and mediators: interactions among lipids, eicosanoids, and cytokines. Am J Clin 1993; 57 (5 Suppl.): S798-800
89. Toborek M, Lee YW, Garrido R, et al. Unsaturated fatty acids selectively induce an inflammatory environment in human endothelial cells. Am J Clin Nutr 2002; 75: 119-25
90. Riserus U, Basu S, Jovinge S, et al. Supplementation with conjugated linoleic acid causes isome-dependent oxidative stress and elevated C-reactive protein: a potential link to fatty acid-induced insulin resistance. Circulation 2002; 106: 1925-9
91. Durand P, Prost M, Loreau N, et al. Impaired homocysteine metabolism and atherothrombotic disease. Lab Invest 2001; 81: 645-72
92. Harpel PC, Zhang X, Borth W. Homocysteine and hemostasis: pathogenic mechanisms predisposing to thrombosis. J Nutr 1996; 126: 1285S-9S
93. Fonseca V, Guba SC, Fink LM. Hyperhomocysteinemia and the endocrine system: implications for atherosclerosis and thrombosis. Endocr Rev 1999; 20: 738-59
94. Hoogeveen EK, Kostense PJ, Jakobs C, et al. Hyperhomocysteinemia increases risk of death, especially in type 2 diabetes: 5-year follow-up of the Hoorn Study. Circulation 2000; 101: 1506-11
95. Chung HY, Kim HJ, Kim JW, et al. The inflammation hypothesis of aging; molecular modulation by calorie restriction. Ann N Y Acad Sci 2001; 928: 327-35
96. Krauss R, Dreon D. Low-density-lipoprotein subclasses and response to a low-fat diet in healthy men. Am J Clin Nutr 1995; 62 (2): S478-87
97. Landlois M, Duprez D, Delanghe J, et al. Serum vitamin C concentration is low in peripheral arterial disease and is associated with inflammation and severity of atherosclerosis. Circulation 2001; 103: 1863-8
98. Stehouwer CD, Gall MA, Twisk JW, et al. Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. Diabetes 2002; 51: 1157-65.
99. Festa A, D'Agostino R, Howard G, et al. Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: the Insulin Resistance Atherosclerosis Study. Kidney Int 2000; 58: 1703-10
100. Fried LP, Borhani NO, Enright P, et al. The Cardiovascular Health Study: design and rationale. Ann Epidemiol 1991; 1: 263-76
101. Joussen AM, Poulaki V, Mitsiades N, et al. Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression. FASEB J 2002; 16: 438-40
102. Baeuerle PA, Baltimore D. NF-kappa B: ten years after. Cell 1996; 87: 13-20
103. Hundal RS, Petersen KF, Mayerson AB, et al. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest 2002; 109: 1321-6
104. Ghanim H, Garg R, Aljada A, et al. Suppression of nuclear factor-kappaB and stimulation of inhibitor kappaB by troglitazone: evidence for an anti-inflammatory effect and a potential antiatherosclerotic effect in the obese. J Clin Endocrinol Metab 2001; 86: 1306-12
105. McFarlane SI, Muniyappa R, Francisco R, et al. Pleiotropic effects of statins: lipid reduction and beyond. J Clin Endocrinol Metab 2002; 87: 1451-8
106. Freeman DJ, Norrie J, Sattar N, et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001; 103: 357-62
107. Patrick L, Uzick M. Cardiovascular disease: C-reactive protein and the inflammatory disease paradigm: HMG-CoA reductase inhibitors, alpha-tocopherol, red yeast rice, and olive oil polyphenols: a review of the literature. Altern Med Rev 2001; 6: 248-71
108. Dessein PH, Joffe BI, Stanwix AE. Effects of disease modifying agents and dietary intervention on insulin resistance and dyslipidemia in inflammatory arthritis: a pilot study [abstract]. Arthritis Res 2002; 4: R12
109. Harper CR, Jacobson TA. The fats of life: the role of omega-3 fatty acids in the prevention of coronary heart disease. Arch Intern Med 2001; 161: 2185-92
110. Johansen O, Seljeflot I, Hostmark AT, et al. The effect of supplementation with omega-3 fatty acids on soluble markers of endothelial function in patients with coronary heart disease. Arterioscler Thromb Vasc Biol 1999; 19: 1681-6
111. Seljeflot I, Arnesen H, Brude IR, et al. Effects of omega-3 fatty acids and/or antioxidants on endothelial cell markers. Eur J Clin Invest 1998; 28: 629-35
112. De Caterina R, Liao JK, Libby P. Fatty acid modulation of endothelial activation. Am J Clin Nutr 2000; 71 (1 Suppl.): S213-23.
113. Abe Y, El-Masri B, Kimball KT, et al. Soluble cell adhesion molecules in hypertriglyceridemia and potential significance on monocyte adhesion. Arterioscler Thromb Vasc Biol 1998; 18: 723-31
114. Marchioli R, Barzi F, Bomba E, et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nett'Infarto Miocardico (GISSI)-Prevenzione. Circulation 2002; 105: 1897-903
115. Iso H, Rexrode KM, Stampfer MJ, et al. Intake of fish and omega-3 fatty acids and risk of stroke in women. JAMA 2001; 285: 304-12